DexCom (NASDAQ:DXCM) Issues Earnings Results

DexCom (NASDAQ:DXCM) issued its quarterly earnings data on Thursday. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05), Zacks reports. DexCom had a return on equity of 31.40% and a net margin of 17.22%.

DexCom Trading Up 0.3 %

DXCM stock traded up $0.22 during mid-day trading on Thursday, reaching $84.09. The company had a trading volume of 6,781,111 shares, compared to its average volume of 3,443,240. The company has a market capitalization of $32.85 billion, a PE ratio of 50.35, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14. The firm has a 50 day moving average of $82.11 and a 200 day moving average of $75.19. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and upped their price target for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Leerink Partners decreased their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Canaccord Genuity Group lifted their price target on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Finally, Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and raised their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.41.

Insider Activity

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 42,342 shares of company stock valued at $3,628,069. Corporate insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.